Enveda secures $311M to bring more nature-derived AI drugs into clinical trials
- ID
- 27849
- Status
- summarized
- Published
- 24 Sep 2026, 3:31 AM
- Fetched
- 24 Sep 2026, 4:22 AM
- Provider
- TechCrunch
- Category
- technology
- Original URL
- https://techcrunch.com/2026/09/23/enveda-secures-311m-to-bring-more-nature-derived-ai-drugs-into-clinical-trials/
- Source URL
- https://techcrunch.com/feed/
Summary
- Score
- 3.0
- Created
- 24 Sep 2026, 4:25 AM
- Tags
- Audience
- ai_ml_learnerssaas_founders
What happened
Enveda, a biotech startup using AI to discover drugs derived from plants and microbes, raised a $311M Series E at a $2B valuation led by Catalio Capital Management, with participation from Iconiq. The valuation doubles what Enveda achieved 12 months ago; the company is currently testing several AI-discovered drug candidates in human clinical trials, including one for severe skin conditions and another for maintaining weight loss after stopping GLP-1s.
Why it matters
This is a biotech funding announcement with little direct impact on builders outside pharma. The only transferable signal is that AI-discovered drug candidates are advancing into human trials, which matters only if you work in or sell into the life-sciences AI tooling space. No action required for general developers or SaaS founders.
Discussion angle
Whether AI drug-discovery startups reaching clinical trials signals a real inflection for applied ML in regulated industries, or whether $2B valuations are premature given zero FDA-approved AI drugs so far.